Join
Live feed
·
PRReleasevia Quantisnow
Praxis Precision Medicines Inc. logo

Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine

ByQuantisnow·Wall Street's wire, on your screen.
PRAX· Praxis Precision Medicines Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRAX (Praxis Precision Medicines Inc.) and more on Quantisnow.